Alice Montoyo

Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon

Alexandra Calmy, Tamara Tovar-Sanchez, Charles Kouanfack et al. · The Lancet HIV · 2020 · 164 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial

Nathalie De Castro, Olivier Marcy, Corine Chazallon et al. · The Lancet Infectious Diseases · 2021 · 29 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +13

Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)

Marwân‐al‐Qays Bousmah, Marie Libérée Nishimwe, Tamara Tovar-Sanchez et al. · PharmacoEconomics · 2020 · 16 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

A community-based healthcare package combining testing and prevention tools, including pre-exposure prophylaxis (PrEP), immediate HIV treatment, management of hepatitis B virus, and sexual and reproductive health (SRH), targeting female sex workers (FSWs) in Côte d’Ivoire: the ANRS 12381 PRINCESSE project

Valentine Becquet, Marcellin Nouaman, Mélanie Plazy et al. · BMC Public Health · 2021 · 13 citations · Full text

Medicine, Community Health, Preventive Medicine +17